5. Roche - Top 15 R&D Budgets

Who: Roche

Based: Switzerland

2006 Pipeline Budget: $5.99 billion (€4.09)

2007 Pipeline News: Roche kicked off the year by pledging to shake up R&D by boosting spending while restructuring its research work around the globe. It divided R&D into five arenas of molecular mechanisms: oncology, virology, inflammation, metabolism and the central nervous system.

The company has made particular strides with cancer and diabetes research--the company has 33 oncology drugs and five diabetes drugs in testing. Roche also pledged to make a number of acquisitions in 2007, which it did throughout the year. There are nine additional indication for its blockbuster cancer drug Avastin in Phase III and three more are pending approval. Overall, the company has 40 drugs in Phase III, 32 in Phase II and 34 in Phase I.

Drugs Pending Approval:
> Xeloda - Oral fluoropyrimidine metastatic colorectal cancer (1st line) combo, oral fluoropyrimidine metastatic colorectal cancer (2nd line) combo
> Avastin - Renal cell carcinoma, metastatic colorectal cancer (1st line) combo oxaliplatin, Metastic breast cancer (1st line) combo taxol
> Nicorandil (Sigmart) - Acute heart failure

Phase III:
> Rituximab MabThera / Rituxan - Rheumatoid arthritis
> Tocilizumab (Actemra) - Rheumatoid arthritis, Systemic Onset of Juvenile Idiopathic arthritis
> Ocrelizumab - Rheumatoid arthritis
> Rituximab (MabThera/ Rituxan) - Chronic lymphocytic leukemia, chronic lymphocytic leukemia (relapsed)
> Rituximab (MabThera / Rituxan) - Maintenance indolent NHL 1st line
> Erlotinib (Tarceva) - Non-small cell lung cancer (1st line maintenance) combo with chemotherapy, Adjuvant non-small cell lung cancer, Inhibitor non-small cell lung cancer (2nd line) combo Avastin
> Capecitabine (Xeloda) - Oral fluoropyrimidine adjuvant CC combo Avastinm, oral fluoropyrimidine adjuvant CC combo Avastin, oral fluoropyrimidine adjuvant breast cancer
> Bevacizumab (Avastin) - Metastatic gastric cancer, adjuvant CC, mBC (1st line) combo non-taxanes, mBC (1st line) combo taxotere, non-small cell lung cancer 1st line maintenance (combo Tarceva), ovarian cancer, pancreatic cancer, prostate cancer, adj non-small cell lung cancer, aggressive NHL, mBC (1st line) combo Herceptin
> Trastuzumab (Herceptin) - Metastatic gastric cancer
> Valganciclovir (Valcyte) - CMV replication
> Rituximab (MabThera/ Rituxan) - Antineutrophil Cytoplasmic Antibodies-associated vasculitis, Systemic Lupus Erythematodes
> Rituximab (MabThera/ Rituxan) - AI PMS, Lupus nephritis
> Bevacizumab (Avastin) - Metastatic breast cancer (2nd line), adjuvant rectal cancer, GIST recurrent
> Tenecteplase (TNKase) - Catheter clearance
> Nicaraven (Antevas) - Subarachnoid hemorrhage
> EPOCH - Chemotherapy induced anemia
> Lucentis - Retinal vein occlusion, diabetic macular edema
> Xolair - Pediatric asthma

Company Pipeline Site: Link

5. Roche - Top 15 R&D Budgets
Read more on

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.